FIGURE 3 from Nucleolar Localization of the RNA Helicase DDX21 Predicts Survival Outcomes in Gynecologic Cancers

Nucleolar DDX21 predicts PARPi sensitivity and niraparib decreases cell growth in endometrial and ovarian cancers. A and B, Dose–response curves showing increasing concentrations of niraparib significantly decreasing cell viability in endometrial (A) and ovarian cancer cells (B) assayed by crystal violet staining. C, Table showing the IC50 values of niraparib in Ishikawa, HEC-1-A, KLE, OVCAR3, and OVCAR4 cells as calculated from experiments in A and B. Table also shows values for the relative levels of DDX21 as measured by immunofluorescence (IF) and Western blot (WB). Basal levels of DDX21, without any treatment in ovarian and endometrial cancer cell lines examined by immunofluorescence (D) and Western blotting (E). Correlation plots showing DDX21 intensity (y-axis) as measured by IF (F) and Western blot (G), and calculated IC50 of niraparib (x-axis). n = 3 (per cell line). Each point corresponds to a different replicate and different cell lines are colored differently; Correlation analysis; *, P H, PARP1 inhibition with niraparib significantly decreases the proliferation of endometrial and ovarian cancer cell lines. Bar graphs showing quantification of the growth of cells at day 6 with different concentrations of niraparib. Each bar represents the mean ± SEM; n = 3. Bars marked with asterisks are significantly different; Student t test; *, P P P